Targeting DNA‐LNPs to Endothelial Cells Improves Expression Magnitude, Duration, and Specificity
Authors:
- Nicolas MarzoliniNMNicolas Marzolini
- Taylor V. BrysgelTBTaylor V. Brysgel
- Ryan J. RahmanRRRyan J. Rahman
- Eno‐Obong EssienEEEno‐Obong Essien
- Jichuan WuJWJichuan Wu
- Manthan N. PatelMPManthan N. Patel
- Sachchidanand TiwariSTSachchidanand Tiwari
- Carolann L. EspyCECarolann L. Espy
- Sabrina A. Santos‐De LeónSLSabrina A. Santos‐De León
Open Access
- 20 January 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (14) , e15480
Abstract
DNA‐lipid nanoparticles (DNA‐LNPs) loaded with inhibitors of the cGAS‐STING pathway enable safe and effective delivery of DNA in vivo. Herein, we report the first instances of extrahepatic DNA‐LNP targeting. DNA‐LNPs conjugated to antibodies against PECAM‐1 or VCAM‐1 target the endothelium of the lungs and brain/spleen, respectively. These LNPs drive robust transgene expression in their target organs, with greater magnitude and duration than untargeted LNPs. Lung specificity of PECAM‐targeted transgene expression increases over two weeks, resulting in markedly higher lung‐to‐liver expression ratios than our previous PECAM‐targeted mRNA‐LNPs. Off‐target liver DNA expression declines to undetectable levels but persists in the lungs, while mRNA expression uniformly decreases due to its short half‐life. We further improve this expression specificity by replacing full‐length antibodies with Fab fragments. Single‐cell analysis reveals a key mechanism underlying the improvements in organ‐specificity: target organ expression is dominated by long‐lived endothelial cells, while off‐target liver delivery and expression are in non‐endothelial cells with shorter half‐lives. Collectively, these studies demonstrate that targeted DNA‐LNPs achieve high levels of organ‐ and cell‐type‐specific transgene expression and thus provide a therapeutic platform for dozens of endothelial‐centric diseases.Keywords
All Related Versions
Funding Information
- National Institutes of Health (‐1DP5OD036159)
- National Institutes of Health (R01‐HL‐153510)
- National Institutes of Health (HL160694)
- National Institutes of Health (‐HL164594)
- National Institutes of Health (‐HL‐157189)
- National Institutes of Health (‐HL‐155106)
- University of Pennsylvania (RRID: SCR_022376)
- American Heart Association (24PRE1195406)
This publication has 53 references indexed in Scilit:
- Conjugation Chemistry Markedly Impacts Toxicity and Biodistribution of Targeted Nanoparticles, Mediated by Complement ActivationAdvanced Materials, 2024
- Physicochemical Targeting of Lipid Nanoparticles to the Lungs Induces Clotting: Mechanisms and SolutionsAdvanced Materials, 2024
- ICAM-1 and VCAM-1: Gatekeepers in various inflammatory and cardiovascular disordersClinica Chimica Acta, 2023
- Targeted drug delivery to the brain endothelium dominates over passive delivery via vascular leak in experimental intracerebral hemorrhageJournal of Controlled Release, 2023
- The replacement of helper lipids with charged alternatives in lipid nanoparticles facilitates targeted mRNA delivery to the spleen and lungsJournal of Controlled Release, 2022
- Novel lipid combination for delivery of plasmid DNA to immune cells in the spleenJournal of Controlled Release, 2021
- PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptakeJournal of Controlled Release, 2018
- Isolation and Culture of Endothelial Cells from Large Vessels2017
- Size and targeting to PECAM vs ICAM control endothelial delivery, internalization and protective effect of multimolecular SOD conjugatesJournal of Controlled Release, 2016
- VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivoBiochimica et Biophysica Acta (BBA) - Biomembranes, 2008